Skip to main
  1. Stocks
  2. Bright Minds Biosciences
  3. Forecast
DRUG

DRUG Stock Forecast & Price Target

DRUG Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Bright Minds Biosciences is attractive because its lead asset BMB-101 is a highly selective 5-HT2C agonist that precisely targets GABA interneurons, aiming to improve seizure control without the somnolence and broader safety liabilities seen with less selective serotonergic drugs. The investment case is strengthened by Phase 2 BREAKTHROUGH data showing a 73.1% median reduction in absence seizures and a 63.3% median reduction in major motor seizures, plus a favorable tolerability profile and a potentially defensible ambulatory EEG endpoint for registrational development. Financially, the company reported C$307.8 million in cash as of June 30, and that balance, along with ongoing work in absence epilepsy, DEEs, and PWS, supports meaningful optionality while clinical-stage risks remain.

Bears say

Bright Minds Biosciences is facing a weakened risk/reward profile after the FDA’s partial clinical hold on the Phase 2 DEE trial, which cites mouse toxicity and insufficient pediatric PK/juvenile toxicity data, increasing regulatory uncertainty and delaying the program. The investment case is heavily dependent on BMB-101’s safety and dosing advantages, yet the company now has a higher 20% discount rate and reduced success probabilities to 50% for both absence seizures and DEEs, suggesting confidence in the asset has deteriorated. Although the drug showed a 73.1% median seizure reduction in absence and a 63.3% reduction in DEE with encouraging tolerability, the room for error is nearly zero because the thesis rests on clinical data that may need significant expansion to restore credibility.

DRUG has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bright Minds Biosciences and is not a guaranteed prediction by Public.com or investment advice.

DRUG Analyst Forecast & Price Prediction

Get the latest DRUG stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in DRUG

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bright Minds Biosciences (DRUG) Forecast

Analysts have given DRUG a Strong Buy based on their latest research and market trends.

According to 7 analysts, DRUG has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $126.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $126.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bright Minds Biosciences (DRUG)


DRUG Analyst Forecast & Price Prediction

Get the latest DRUG stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in DRUG

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover DRUG stock data and trends